rozlytrek
roche registration gmbh - entrectinib - cancer; carcinoma, non-small-cell lung - antineoplastilised ained - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.
erlotinib sandoz õhukese polümeerikattega tablett
sandoz pharmaceuticals d.d. - erlotiniib - õhukese polümeerikattega tablett - 150mg 30tk
erlotinib actavis õhukese polümeerikattega tablett
actavis group ptc ehf. - erlotiniib - õhukese polümeerikattega tablett - 150mg 30tk
erlotinib teva õhukese polümeerikattega tablett
teva b.v. - erlotiniib - õhukese polümeerikattega tablett - 150mg 1tk 30tk
erlotinib teva pharma õhukese polümeerikattega tablett
teva pharma b.v. - erlotiniib - õhukese polümeerikattega tablett - 150mg 1tk 30tk
erlotinib sandoz õhukese polümeerikattega tablett
sandoz pharmaceuticals d.d. - erlotiniib - õhukese polümeerikattega tablett - 25mg 30tk
erlotinib teva õhukese polümeerikattega tablett
teva b.v. - erlotiniib - õhukese polümeerikattega tablett - 100mg 1tk 30tk
erlotinib actavis õhukese polümeerikattega tablett
teva b.v. - erlotiniib - õhukese polümeerikattega tablett - 100mg 30tk
erlotinib actavis õhukese polümeerikattega tablett
actavis group ptc ehf. - erlotiniib - õhukese polümeerikattega tablett - 25mg 30tk
erlotinib viatris õhukese polümeerikattega tablett
viatris limited - erlotiniib - õhukese polümeerikattega tablett - 100mg 30tk